NCT06969001已完成1 期
A Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Administration of SCAI-005 Ophthalmic Solution in Healthy Korean Subjects
SCAI Therapeutics1 个研究点 分布在 1 个国家目标入组 48 人开始时间: 2025年5月29日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Safety Evaluation: Incidence, type, and severity of Adverse Events (AE)
研究概览
简要总结
To assess the single-dose and multiple-dose pharmacokinetics (PK), safety and tolerability of SCAI-005 eyedrops(axitinib) in healthy volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Other
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 19 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult subjects aged 19 to 50 years at the time of screening
- •Male subjects with a body weight of 55.0 kg or more, Female subjects with a body weight of 50kg or more, and within ±20% of ideal body weight at the time of screening
- •Subject who voluntarily agrees to participate in this study and has given a written informed consent, after fully understanding the detailed explanation of this study
排除标准
- •Subjects with symptoms suggestive of an acute disease at the time of screening
- •Subjects with clinically significant and active diseases related to cardiovascular system, gastrointestinal system, respiratory system, endocrine system, neuropsychiatric system, hematologic/oncologic system
- •Subjects meeting any of the following criteria based on examination during screening:
- •AST, ALT > 1.5 X ULN
- •Total bilitubin > 1.5 X ULN
- •eGFR (estimated Glomerular Filtration Rate) < 90 mL/min/1.73 m2
- •serological test result = positive
- •Subjects with systolic blood pressure of 90 mmHg or less, or 150 mmHg or more, or diastolic blood pressure of 50 mmHg or less, or 100 mmHg or more after sitting for at least 5 minutes during screening (Visit 1)
- •Subjects meeting any of the following criteria based on ophthalmological examination during screening:
- •Best corrected visual acuity < 0.6
- •IOP > 21 mmHg
- •difference in IOP between both eyes > 4mmHg
- •subjects who are assessed ineligible due to abnormal findings in other ophthalmonlogical examinations
- •History or suspicion of conditions affecting visual organs such as keratitis, iritis, uveitis, retinitis, dry eye syndrome, strabismus within 12months prior to screening visit
- •Ophthalmologic surgery within 12 months prior to screening visit
- •Subjects with acute or chronic eye diseases requiring topical eyedrops at the time of screening
- •Experience of adverse effects from contact lens use, or contact lens use within one month prior to screening visit, or inability to abstain from contact lens use during the clinical trial
- •Subjects with a history of drug abuse or a positive result on a urine drug test at screening
- •Subjects with a history of hypersensitivity to the investigational drug, or to drugs in the same class as the active ingredients
- •Subjects who have participated in another clinical trial and received an investigational drug within 6 months prior to the anticipated first dose
- •Subjects who have taken drug metabolism inducers or inhibitors, such as barbiturates, within one month prior to the expected first dosing date
- •Subjects who have donated whole blood within 2 months, or component blood within 20 days
- •Subjects who have taken any prescription drugs or oriental medicine within 2 weeks of the expected first dosing date, or any over-the-counter drugs or vitamins within 1 week of the expected first dosing date
- •Subjects unable to restrict grapefruit or grapefruit-containing food consumption from 7 days prior to the anticipated first dose through the duration of the clinical trial.
- •Subjects who regularly consume caffeine (e.g., coffee or green tea more than 5 units/day) or are unable to abstain from caffeine-containing foods from 24 hours prior to hospitalization to discharge
- •Subjects who have consumed alcohol regularly (more than 210g/week) or are unable to abstain from alcohol from 24 hours prior to hospitalization to discharge
- •Subjects who have regularly smoked (including e-cigarettes, more than 10 cigarettes/day) or are unable to abstain from 24 hours prior to hospitalization to discharge
- •Female participants who are pregnant, or are breastfeeding
- •Subjects who, during the entire clinical trial period and for at least 90 days after the last dose of the investigational drug, cannot or do not agree to use medically acceptable double contraception methods, or who do not agree to refrain from donating sperm during this period
- •Subjects deemed unsuitable for participation by the investigator for other reasons
研究组 & 干预措施
Single Ascending Dose
Experimental
Day 1: One time administration, 8 subjects randomized 3:1 to SCAI-005 or placebo in each cohort
干预措施: SCAI-005 0.08% or placebo 2drops (Drug)
Multiple Ascending Dose
Experimental
Three times administration daily (TID) for 7days, 8 subjects randomized 3:1 to SCAI-005 or placebo in each cohort
干预措施: SCAI-005 0.04% or placebo (Drug)
Single Ascending Dose
Experimental
Day 1: One time administration, 8 subjects randomized 3:1 to SCAI-005 or placebo in each cohort
干预措施: SCAI-005 0.04% or placebo (Drug)
Single Ascending Dose
Experimental
Day 1: One time administration, 8 subjects randomized 3:1 to SCAI-005 or placebo in each cohort
干预措施: SCAI-005 0.08% or placebo (Drug)
Multiple Ascending Dose
Experimental
Three times administration daily (TID) for 7days, 8 subjects randomized 3:1 to SCAI-005 or placebo in each cohort
干预措施: SCAI-005 0.08% or placebo (Drug)
Multiple Ascending Dose
Experimental
Three times administration daily (TID) for 7days, 8 subjects randomized 3:1 to SCAI-005 or placebo in each cohort
干预措施: SCAI-005 0.08% or placebo 2drops (Drug)
结局指标
主要结局
Safety Evaluation: Incidence, type, and severity of Adverse Events (AE)
时间窗: 15days
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
GW117 ODT （Orally Disintegrating Tablets） Safety and Pharmacokinetics Study in Healthy SubjectsMajor Depressive DisorderNCT06964711Beijing Greatway Pharmaceutical Technology Co.,Ltd.92
已完成
1 期
Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy SubjectsInfluenzaNCT01990846Autoimmune Technologies, LLC68
已完成
1 期
A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian ParticipantsHealthy VolunteersNCT05806359Bristol-Myers Squibb33
终止
1 期
Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human VolunteersExcessive SleepinessMajor Depressive DisorderNCT04618263Gate Neurosciences, Inc18
已完成
1 期
A Study of Nipocalimab in Healthy Male and Female ParticipantsHealthyNCT04848558Janssen Research & Development, LLC89